Atlas Trials

A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide

Clinical trial NCT05901649 · COMPLETED

Trial details

NCT number
NCT05901649
Sponsor
Janssen-Cilag Ltd.
Status
COMPLETED
Study type
OBSERVATIONAL
Metastatic Hormone-sensitive Prostate Cancer
Start date
2023-07-05
Primary completion
2026-06-16
Enrollment
505

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.